Latest Blogs

Feb 19, 2020
Let’s look critically at the prospective trial evaluating the association of ringing a bell with distress experienced by patients with cancer.
Feb 10, 2020
As we begin our work in 2020, I am excited that we are building on the remarkable successes of 2019, and the years before, with growing collaboration and sharpening focus. 
Feb 04, 2020
As we celebrate the 20th anniversary of World Cancer Day this February 4, it’s important to recognize that we are making progress in addressing cancer.
Feb 04, 2020
World Cancer Day 2020 is about every one of us, and about asking for our commitment to do something to prevent cancer and support people and communities deal with cancer.
Subscribe to this column

Don S. Dizon, MD, FACP, FASCO

Don S. Dizon, MD, FACP, FASCO, is head of Women's Cancers at Lifespan Cancer Institute, director of Medical Oncology at Rhode Island Hospital, and a professor of medicine at The Warren Alpert Medical School of Brown University. Dr. Dizon serves as chair of ASCO's Social Media Working Group and is a past chair of the Cancer Communications Committee. In addition to his regular column on ASCOconnection.org, which has been honored with APEX awards in 2013 and 2014, he is a blogger for The Oncologist and a section editor of Gynecologic Oncology at UpToDate. Dr. Dizon is a member of the Journal of Clinical Oncology Editorial Board, and editor in chief of the ASCO Educational BookFollow Dr. Dizon on Twitter @drdonsdizon.

Sep 12, 2017
I applaud the Foundation for Women’s Cancers for highlighting the importance of trials, and join them in their push for more trial options for not only my own patients, but for all patients with cancer.
Aug 29, 2017
As I prepare to take on a new professional position, I have been reflecting on what academic medicine means, and how to thrive in it.
Aug 01, 2017
Yes, "at least" my patient was still alive. But, at the end of the day, I knew that would not be comforting. “At least” is never enough, because when it comes to life, most of us—cancer or no cancer—always want more.
Jun 20, 2017
New immunotherapies are offering astounding responses, but my patient's remission came at the cost of debilitating toxicity. How much is too much to bear?
Jun 08, 2017
At the Plenary Session of this year’s ASCO Annual Meeting, the results of a longitudinal trial begun in 2007 showed me that patient engagement is much more important that I had imagined.
May 30, 2017
The phrase "the fight against cancer" assumes only two outcomes: remission or death, no middle ground. Today more than ever, nothing is further from reality.

Pages